Sanofi (NASDAQ:SNY) Q4 2024 Results Conference Call January 30, 2025 9:00 AM ET
Company Participants
Thomas Larsen - Head of Investor Relations
Paul Hudson - Chief Executive Officer
Francois Roger - Executive Vice President, Chief Financial Officer
Thomas Triomphe - Executive Vice President, Vaccines
Brian Foard - Executive Vice President, Head of Specialty Care
Houman Ashrafian - Executive Vice President, Head of Research and Development
Conference Call Participants
Luisa Hector - Berenberg
Graham Parry - BofA
Seamus Fernandez - Guggenheim
Peter Welford - Jefferies
Jo Walton - UBS
Richard Vosser - JPMorgan
Florent Cespedes - Bernstein Securities
David Risinger - Leerink
Peter Verdult - BNP Exane
Emmanuel Papadakis - Deutsche Bank
Eric Berrigaud - Stifel
Ricardo Benevides - Santander
Thomas Larsen
Welcome to the Q4 and Full Year 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com.
Please turn to Slide number 3. Here we have the usual forward-looking statements. We would like to remind you that information presented in this call contains forward-looking statements, which are subject to substantial risks and uncertainties that may cause actual results to differ materially.
We encourage you to read the disclaimer in our slide presentation. In addition, we refer you to our Form 20-F on file with the U.S. SEC and our French registration document for a description of these risk factors. Financials reported are under the new reporting scope that excludes Opella Consumer Health.
As usual, we will be making comments on our performance using constant exchange rates and other non-IFRS measures. Numbers used are in million euros and for Q4 2024 unless stated otherwise.
Please turn to Slide number 4. First, we have a presentation then we'll take your questions. Because this is a full year results, we have a few more slides, we still have time for lot